AbbVie Overview

  • Status
  • Public

  • Employees
  • 50,000

Employees

  • Stock Symbol
  • ABBV

Stock Symbol

  • Investments
  • 36

  • Share Price
  • $173.78
  • (As of Tuesday Closing)

AbbVie General Information

Description

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Contact Information

Website
www.abbvie.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 1 North Waukegan Road
  • North Chicago, IL 60064
  • United States
+1 (800)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NYS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1 North Waukegan Road
  • North Chicago, IL 60064
  • United States
+1 (800)

AbbVie Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbbVie Stock Performance

As of 22-Apr-2025, AbbVie’s stock price is $173.78. Its current market cap is $307B with 1.77B shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$173.78 $170.16 $153.58 - $218.66 $307B 1.77B 7.43M $2.40

AbbVie Financials Summary

As of 31-Dec-2024, AbbVie has a trailing 12-month revenue of $56.3B.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 377,853,835 377,853,835 321,096,334 343,564,135
Revenue 56,334,000 56,334,000 54,318,000 58,054,000
EBITDA 14,262,000 14,262,000 16,632,000 23,988,000
Net Income 4,278,000 4,278,000 4,863,000 11,836,000
Total Assets 135,161,000 135,161,000 134,711,000 138,805,000
Total Debt 67,144,000 67,144,000 59,385,000 63,271,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AbbVie Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AbbVie‘s full profile, request access.

Request a free trial

AbbVie Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (wi
Drug Discovery
North Chicago, IL
50,000 As of 2024

Cambridge, MA
 

Foster City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AbbVie Competitors (40)

One of AbbVie’s 40 competitors is Biogen, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biogen Formerly VC-backed Cambridge, MA
Gilead Sciences Formerly VC-backed Foster City, CA
Eli Lilly and Company Corporation Indianapolis, IN
Amgen Formerly PE-Backed Thousand Oaks, CA
Roche Corporation Basel, Switzerland
You’re viewing 5 of 40 competitors. Get the full list »

AbbVie Patents

  • 9,425

    Total Documents Applications and Grants

  • Total Patents Families

  • 4,213

    Granted

  • 591

    Pending

  • Expiring in next 12 mo

AbbVie Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250059280-A1 Methods of treating human immunodeficiency virus (hiv) disease Pending 15-Aug-2023
US-20250049789-A1 Methods of treating alopecia araeta Inactive 08-Aug-2023
US-D1065814-S1 Carrying pack for medical device Active 22-Jun-2023
JP-2024173752-A Anti-human cd33 bet degrader antibody-drug conjugates Pending 01-Jun-2023
US-20250000993-A1 Anti-human cd33 bet degrader antibody-drug conjugates Pending 01-Jun-2023 A61K47/6849
To view AbbVie’s complete patent history, request access »

AbbVie Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbbVie Investments & Acquisitions (36)

AbbVie’s most recent deal was a Merger/Acquisition with Nimble Therapeutics for . The deal was made on 23-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nimble Therapeutics 23-Jan-2025 Merger/Acquisition Drug Discovery
Aliada Therapeutics 11-Dec-2024 Merger/Acquisition Discovery Tools (Healthcare)
EvolveImmune Therapeutics 29-Oct-2024 Later Stage VC Drug Discovery
Cerevel Therapeutics 01-Aug-2024 Merger/Acquisition Drug Discovery
Celsius Therapeutics 27-Jun-2024 Merger/Acquisition Biotechnology
You’re viewing 5 of 36 investments and acquisitions. Get the full list »

AbbVie ESG

Risk Overview

Risk Rating

Updated February, 15, 2025

23.87 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Pharmaceuticals

Subindustry

of 430

Rank

Percentile

To view AbbVie’s complete esg history, request access »

AbbVie Exits (4)

AbbVie’s most recent exit was on 11-Feb-2019 from Lyndra Therapeutics. The exit was categorized as with 15 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Lyndra Therapeutics 11-Feb-2019 Completed
  • 15 buyers
BioArctic 20-Sep-2016 Completed
  • 4 buyers
Reata Pharmaceuticals 26-May-2016 Completed
Reata Pharmaceuticals 13-Jul-2011 Later Stage VC Completed
  • 3 buyers
To view AbbVie’s complete exits history, request access »

AbbVie Affiliates

Subsidiaries (10)

Name Industry Location Year Founded
Aliada Therapeutics Boston, MA 2021
Nimble Therapeutics Madison, WI 2019
DJS Antibodies Bicester, United Kingdom 2014
Abbott - AbbVie Multiple Employer Pension Plan Abbott Park City, IL 2013
AbbVie (Women's Drug Portfolio) Dublin, Ireland 2012
You’re viewing 5 of 10 affiliates. Get the full list.  »

AbbVie FAQs

  • Where is AbbVie headquartered?

    AbbVie is headquartered in North Chicago, IL.

  • What is the size of AbbVie?

    AbbVie has 50,000 total employees.

  • What industry is AbbVie in?

    AbbVie’s primary industry is Drug Discovery.

  • Is AbbVie a private or public company?

    AbbVie is a Public company.

  • What is AbbVie’s stock symbol?

    The ticker symbol for AbbVie is ABBV.

  • What is the current stock price of AbbVie?

    As of 22-Apr-2025 the stock price of AbbVie is $173.78.

  • What is the current market cap of AbbVie?

    The current market capitalization of AbbVie is $307B.

  • What is AbbVie’s current revenue?

    The trailing twelve month revenue for AbbVie is $56.3B.

  • Who are AbbVie’s competitors?

    Biogen, Gilead Sciences, Eli Lilly and Company, Amgen, and Roche are some of the 40 competitors of AbbVie.

  • What is AbbVie’s annual earnings per share (EPS)?

    AbbVie’s EPS for 12 months was $2.40.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »